Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

AIMS: Catumaxomab is the first EMEA approved trifunctional anti-EpCAM×anti-CD3 antibody for the treatment of cancer patients with malignant ascites. A phase II pharmacokinetic study was conducted to determine local and systemic antibody concentrations and anti-drug antibody (ADA) development. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruf, Peter, Kluge, Michael, Jäger, Michael, Burges, Alexander, Volovat, Constantin, Heiss, Markus Maria, Hess, Jürgen, Wimberger, Pauline, Brandt, Birgit, Lindhofer, Horst
Formato: Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2010
Materias:
Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878603/
https://www.ncbi.nlm.nih.gov/pubmed/20565453
http://dx.doi.org/10.1111/j.1365-2125.2010.03635.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878603/
https://www.ncbi.nlm.nih.gov/pubmed/20565453
http://dx.doi.org/10.1111/j.1365-2125.2010.03635.x

Ejemplares similares